Results 51 to 60 of about 52,178 (281)

Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process

open access: yesMicrobial Cell Factories, 2019
BackgroundThe production of therapeutically active single chain variable fragment (scFv) antibody is still challenging in E. coli due to the aggregation propensity of recombinant protein into inclusion bodies (IBs).
A. Sarker, A. Rathore, R. Gupta
semanticscholar   +1 more source

Nonspecificity in a nonimmune human scFv repertoire [PDF]

open access: yesmAbs, 2017
Efforts to develop effective antibody therapeutics are frequently hampered by issues such as aggregation and nonspecificity, often only detected in late stages of the development process. In this study, we used a high throughput cross-reactivity assay to select nonspecific clones from a naïve human repertoire scFv library displayed on the surface of ...
Kelly, Ryan L.   +3 more
openaire   +2 more sources

Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity [PDF]

open access: yes, 2008
Although expanded polyglutamine (polyQ) repeats are inherently toxic, causing at least nine neurodegenerative diseases, the protein context determines which neurons are affected.
Bugg, Charles W.   +5 more
core   +2 more sources

A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer

open access: yesClinical Cancer Research, 2019
Purpose: The B7 homolog 4 (B7-H4, VTCN1) is an immune checkpoint molecule that negatively regulates immune responses and is known to be overexpressed in many human cancers.
A. Iizuka   +11 more
semanticscholar   +1 more source

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

open access: yesAntibodies, 2018
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds.
Pallavi Bhatta, David P. Humphreys
doaj   +1 more source

Expression of Functional Anti-p24 scFv 183-H12-5C in HEK293T and Jurkat T Cells [PDF]

open access: yesAdvanced Pharmaceutical Bulletin, 2017
Purpose: More than half of the diagnostic and therapeutic recombinant protein production depends on mammalian-based expression system. However, the generation of recombinant antibodies remains a challenge in mammalian cells due to the disulfide bond ...
Mohammad Tasyriq Che Omar
doaj   +1 more source

A novel variable antibody fragment dimerized by the dHLX peptide with enhanced affinity against amantadine compared to its corresponding scFv antibody

open access: yesFood and Agricultural Immunology, 2018
Amantadine (AMA) is an illegally used antiviral drug in the poultry industry, it is necessary to establish a fast, accurate and time-saving detection method for poultry food. The antibody-based immunoassay can achieve fast and accurate requirements.
Sanlei Xie   +5 more
doaj   +1 more source

Selection of novel human scFvs against cancer antigen IL1RAP by phage and yeast surface display technology

open access: yesBiotechnology & Biotechnological Equipment, 2020
The objective of this study was isolation of humanized single-chain variable fragment (scFv) antibodies against IL1RAP, a promising cancer marker in leukemia and other tumors.
Shixin Duan   +5 more
doaj   +1 more source

Purification of a Novel Anti-VEGFR2 Single Chain Antibody Fragmentand Evaluation of Binding Affinity by Surface Plasmon Resonance [PDF]

open access: yesAdvanced Pharmaceutical Bulletin, 2019
Purpose: The single-chain variable fragment (scFv) domain of antibodies is now considered asone of the therapeutic tools that can be produced by phage display technology (PDT).
Shirafkan Kordi   +4 more
doaj   +1 more source

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line [PDF]

open access: yesInternational Journal of Molecular Sciences, 2020
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial.
Chung Hyo Kang   +6 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy